Slanix Alex

Slanix Paul Alex, Pharm.D., is President and Portfolio Manager, Public Equity at Ally Bridge Group, based in Miami, Florida. In this role since 2024, he directly oversees the firm’s public equity strategy, focusing on sourcing, diligence, and portfolio construction of investments in innovative healthcare and life sciences companies, particularly in biotechnology, pharmaceuticals, and medical technology.

Dr. Alex’s investment expertise centers on the public markets healthcare sector, with a particular emphasis on high-impact biopharmaceutical and medical innovation. Prior to joining Ally Bridge Group in 2023, he was a founding Partner and Senior Analyst at Tri Locum Partners and held investment analyst roles at Consonance Capital Management. Earlier in his career, he gained foundational experience covering biotechnology equities as a Vice President in equity research at RBC Capital Markets and as an analyst at Credit Suisse, further strengthening his domain knowledge in life sciences investing.

A licensed clinical pharmacist, Dr. Alex holds a Doctor of Pharmacy (Pharm.D.) degree from St. John’s University. He is recognized for his integrative expertise bridging scientific, operational, and capital markets perspectives, and is noted for his recent appointment to the board of ProMIS Neurosciences, reflecting both his leadership at Ally Bridge and his reputation as a champion of innovative biotech investments that address unmet medical needs.